$NVAX
NOVAVAX INC Stock $nvax

$nvax Overview Financials Valuation SEC Filings Company Website

2012 Q4 Form 10-Q Financial Statement

#000114420412060842 Filed on November 09, 2012

Income Statement

Concept	2012 Q4	2012 Q3	2011 Q3
Revenue	$4.567M	$5.765M	$5.008M
YoY Change	-21.86%	15.12%	2404.0%
Cost Of Revenue	$2.000M	$3.838M	$2.190M
YoY Change	-37.5%	75.25%
Gross Profit	$2.600M	$1.927M	$2.818M
YoY Change	0.0%	-31.62%
Gross Profit Margin	56.93%	33.43%	56.27%
Selling, General & Admin	$2.500M	$2.100M	$2.700M
YoY Change	0.0%	-22.22%	-3.57%
% of Gross Profit	96.15%	108.98%	95.81%
Research & Development	$9.600M	$6.642M	$4.049M
YoY Change	118.18%	64.04%	-48.75%
% of Gross Profit	369.23%	344.68%	143.68%
Depreciation & Amortization	$500.0K	$400.0K	$400.0K
YoY Change	25.0%	0.0%	0.0%
% of Gross Profit	19.23%	20.76%	14.19%
Operating Expenses	$12.10M	$6.642M	$4.049M
YoY Change	75.36%	64.04%	-62.16%
Operating Profit	-$9.500M	-$6.849M	-$3.968M
YoY Change	120.93%	72.61%
Interest Expense	$1.400M	$6.000K	$2.000K
YoY Change	180.0%	200.0%	-99.0%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00
YoY Change
Pretax Income	-$8.000M	-$7.217M	-$3.212M
YoY Change	116.22%	124.69%	-69.12%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$8.000M	-$7.217M	-$3.212M
YoY Change	116.22%	124.69%	-68.51%
Net Earnings / Revenue	-175.17%	-125.19%	-64.14%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.194M	-$1.075M	-$551.7K
COMMON SHARES
Basic Shares Outstanding	147.9M	133.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2012 Q4	2012 Q3	2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$44.10M	$28.40M	$19.60M
YoY Change	140.98%	44.9%	-46.88%
Cash & Equivalents	$17.40M	$10.74M	$14.32M
Short-Term Investments	$26.70M	$17.70M	$5.300M
Other Short-Term Assets	$171.0K	$235.0K	$2.800M
YoY Change	-89.02%	-91.61%	833.33%
Inventory
Prepaid Expenses	$2.559M	$2.807M
Receivables	$1.011M	$2.469M	$3.900M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$50.41M	$36.48M	$26.30M
YoY Change	93.07%	38.72%	-30.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.46M	$9.815M	$7.500M
YoY Change	67.07%	30.87%	-8.54%
Goodwill	$33.14M	$33.14M
YoY Change	0.0%
Intangibles	$0.00
YoY Change
Long-Term Investments	$6.200M
YoY Change
Other Assets	$351.0K	$350.0K	$200.0K
YoY Change	-25.16%	75.0%	0.0%
Total Long-Term Assets	$51.94M	$44.06M	$40.80M
YoY Change	28.34%	8.0%	-1.69%
TOTAL ASSETS
Total Short-Term Assets	$50.41M	$36.48M	$26.30M
Total Long-Term Assets	$51.94M	$44.06M	$40.80M
Total Assets	$102.3M	$80.55M	$67.10M
YoY Change	53.73%	20.04%	-15.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.228M	$2.203M	$2.400M
YoY Change	22.04%	-8.21%	-29.41%
Accrued Expenses	$7.275M	$6.031M	$3.900M
YoY Change	60.67%	54.64%	-32.76%
Deferred Revenue
YoY Change
Short-Term Debt	-$157.0K	$0.00	$0.00
YoY Change	685.0%
Long-Term Debt Due	$200.0K	$200.0K	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$11.68M	$10.44M	$6.700M
YoY Change	54.04%	55.84%	-29.47%
LONG-TERM LIABILITIES
Long-Term Debt	$1.000M	$1.000M	$300.0K
YoY Change	233.33%	233.33%	0.0%
Other Long-Term Liabilities		$7.700M	$5.400M
YoY Change		42.59%	116.0%
Total Long-Term Liabilities	$0.00	$8.700M	$5.700M
YoY Change	-100.0%	52.63%	103.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.68M	$10.44M	$6.700M
Total Long-Term Liabilities	$0.00	$8.700M	$5.700M
Total Liabilities	$22.11M	$19.17M	$12.50M
YoY Change	73.69%	53.36%	1.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$358.2M	-$350.1M
YoY Change	8.65%
Common Stock	$1.484M	$1.360M
YoY Change	26.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.450M	$2.450M
YoY Change	0.0%
Treasury Stock Shares	455.4K shares	$455.4K
Shareholders Equity	$80.24M	$61.38M	$54.60M
YoY Change
Total Liabilities & Shareholders Equity	$102.3M	$80.55M	$67.10M
YoY Change	53.73%	20.04%	-15.38%

Cashflow Statement

Concept	2012 Q4	2012 Q3	2011 Q3
OPERATING ACTIVITIES
Net Income	-$8.000M	-$7.217M	-$3.212M
YoY Change	116.22%	124.69%	-68.51%
Depreciation, Depletion And Amortization	$500.0K	$400.0K	$400.0K
YoY Change	25.0%	0.0%	0.0%
Cash From Operating Activities	-$3.200M	-$4.700M	-$3.400M
YoY Change	14.29%	38.24%	-59.04%
INVESTING ACTIVITIES
Capital Expenditures	-$2.100M	-$1.100M	-$200.0K
YoY Change	950.0%	450.0%	-71.43%
Acquisitions
YoY Change
Other Investing Activities	-$15.00M	-$6.200M	$3.900M
YoY Change	-1600.0%	-258.97%	-221.88%
Cash From Investing Activities	-$17.20M	-$7.300M	$3.600M
YoY Change	-2250.0%	-302.78%	-190.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$26.90M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	27.00M	7.400M	900.0K
YoY Change	1400.0%	722.22%	-95.29%
NET CHANGE
Cash From Operating Activities	-3.200M	-4.700M	-3.400M
Cash From Investing Activities	-17.20M	-7.300M	3.600M
Cash From Financing Activities	27.00M	7.400M	900.0K
Net Change In Cash	6.600M	-4.600M	1.100M
YoY Change	-3400.0%	-518.18%	-83.82%
FREE CASH FLOW
Cash From Operating Activities	-$3.200M	-$4.700M	-$3.400M
Capital Expenditures	-$2.100M	-$1.100M	-$200.0K
Free Cash Flow	-$1.100M	-$3.600M	-$3.200M
YoY Change	-57.69%	12.5%	-57.89%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
	dei	Document Period End Date DocumentPeriodEndDate	2012-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001000694
CY2012Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	147941442
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	NOVAVAX INC.
	dei	Trading Symbol TradingSymbol	NVAX
CY2011Q4	nvax	Additional Tenant Improvement Allowance AdditionalTenantImprovementAllowance	3000000	USD
CY2012Q3	nvax	Auction Rate Securities Par Value AuctionRateSecuritiesParValue	5100000	USD
	nvax	Average Share Price AverageSharePrice	1.70
	nvax	Capital Lease Obligation Equipment Purchased CapitalLeaseObligationEquipmentPurchased	399000	USD
	nvax	Capital Lease Obligation Equipment Purchased CapitalLeaseObligationEquipmentPurchased		USD
CY2012Q3	nvax	Capital Lease Periodic Payment CapitalLeasePeriodicPayment	6325	USD
CY2012Q3	nvax	Capital Leases Of Lessee Effective Interest Rate CapitalLeasesOfLesseeEffectiveInterestRate	0.065
CY2012Q3	nvax	Common Stock Value Authorized Prior Agreement CommonStockValueAuthorizedPriorAgreement	50000000	USD
CY2012Q3	nvax	Debt Instrument Term DebtInstrumentTerm	P42M
	nvax	Deposits For Acquisition Of Property And Equipment DepositsForAcquisitionOfPropertyAndEquipment	500000	USD
CY2012Q3	nvax	Common Stock Value Authorized CommonStockValueAuthorized	50000000	USD
CY2008Q3	nvax	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	0.5
CY2008Q3	nvax	Common Shares Per Unit CommonSharesPerUnit	1.0
	nvax	Deposits For Acquisition Of Property And Equipment DepositsForAcquisitionOfPropertyAndEquipment		USD
CY2012Q3	nvax	Joint Venture Percentage Owned By Others JointVenturePercentageOwnedByOthers	0.8
CY2011Q4	nvax	Leased Facility Square Footage LeasedFacilitySquareFootage	74000
CY2012Q3	nvax	Lease Term LeaseTerm	P59M
CY2012Q3	nvax	Loan Agreement Future Minimum Payments Due LoanAgreementFutureMinimumPaymentsDue	550000	USD
CY2012Q3	nvax	Loan Agreement Future Minimum Payments Due In Rolling Year Four LoanAgreementFutureMinimumPaymentsDueInRollingYearFour	40000	USD
CY2012Q3	nvax	Loan Agreement Future Minimum Payments Due In Rolling Year Three LoanAgreementFutureMinimumPaymentsDueInRollingYearThree	157000	USD
CY2012Q3	nvax	Loan Agreement Future Minimum Payments Due In Rolling Year Two LoanAgreementFutureMinimumPaymentsDueInRollingYearTwo	157000	USD
CY2012Q3	nvax	Loan Agreement Future Minimum Payments Next Rolling Twelve Months LoanAgreementFutureMinimumPaymentsNextRollingTwelveMonths	157000	USD
CY2012Q3	nvax	Loan Agreement Future Minimum Payments Remainder Of Fiscal Year LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear	39000	USD
	nvax	Marketable Securities Original Maximum Maturity MarketableSecuritiesOriginalMaximumMaturity	P1Y
	nvax	Marketable Securities Original Minimum Maturity MarketableSecuritiesOriginalMinimumMaturity	P90D
	nvax	Master Service Agreement Purchases MasterServiceAgreementPurchases	400000	USD
	nvax	Master Services Agreement Amount Of Services To Be Provided Minimum MasterServicesAgreementAmountOfServicesToBeProvidedMinimum	7500000	USD
CY2012Q3	nvax	Number Of Auction Rate Securities Included In Investments NumberOfAuctionRateSecuritiesIncludedInInvestments	3
	nvax	Percent Of The Shortfall Amount Exceeding Two Million PercentOfTheShortfallAmountExceedingTwoMillion	0.5
CY2012Q3	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	182000	USD
CY2011Q3	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration		USD
	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	182000	USD
	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration		USD
CY2012Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	493000	USD
CY2011Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	542000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1668000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1677000	USD
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	383948000	USD
	nvax	Settlement Of Notes Receivable SettlementOfNotesReceivable		USD
	nvax	Settlement Of Notes Receivable SettlementOfNotesReceivable	1522000	USD
	nvax	Shortfall Amount Payable In Full ShortfallAmountPayableInFull	2000000	USD
CY2011Q4	nvax	Tenant Allowance Interest Rate TenantAllowanceInterestRate	0.08
CY2011Q4	nvax	Tenant Improvement Allowance TenantImprovementAllowance	2500000	USD
CY2012Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2203000	USD
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2645000	USD
CY2012Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2469000	USD
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1965000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments		USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-317000	USD
CY2012Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6031000	USD
CY2011Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4528000	USD
CY2012Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1036000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	832000	USD
CY2012Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	411558000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12951625
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11119476
	us-gaap	Asset Impairment Charges AssetImpairmentCharges		USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	60000	USD
CY2012Q3	us-gaap	Assets Assets	80546000	USD
CY2011Q4	us-gaap	Assets Assets	66576000	USD
CY2012Q3	us-gaap	Assets Current AssetsCurrent	36484000	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	26109000	USD
CY2012Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	16636000	USD
CY2011Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	3373000	USD
CY2012Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	17672000	USD
CY2011Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	4205000	USD
CY2012Q3	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	17672000	USD
CY2011Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	4205000	USD
CY2012Q3	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	1036000	USD
CY2011Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	832000	USD
CY2012Q3	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1		USD
CY2011Q4	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1		USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1365000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	168000	USD
CY2012Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	57000	USD
CY2011Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent		USD
CY2012Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	252000	USD
CY2011Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent		USD
CY2012Q3	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	360000	USD
CY2008Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	3.62
CY2008Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3343325
CY2012Q3	us-gaap	Capital Leases Future Minimum Payments Due In Rolling After Year Five CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive	44000	USD
CY2012Q3	us-gaap	Capital Leases Future Minimum Payments Due In Rolling Year Five CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive	76000	USD
CY2012Q3	us-gaap	Capital Leases Future Minimum Payments Due In Rolling Year Four CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour	76000	USD
CY2012Q3	us-gaap	Capital Leases Future Minimum Payments Due In Rolling Year Three CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree	76000	USD
CY2012Q3	us-gaap	Capital Leases Future Minimum Payments Due In Rolling Year Two CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo	76000	USD
CY2012Q3	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	51000	USD
CY2012Q3	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	309000	USD
CY2012Q3	us-gaap	Capital Leases Future Minimum Payments Remainder Of Fiscal Year CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear	12000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10738000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14104000	USD
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14318000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8061000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3366000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6257000	USD
CY2012Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2012Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	136003676
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	117480867
CY2012Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	135548246
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	117025437
CY2012Q3	us-gaap	Common Stock Value CommonStockValue	1360000	USD
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	1175000	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7121000	USD
CY2011Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3209000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20268000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15518000	USD
CY2012Q3	us-gaap	Contract Revenue Cost ContractRevenueCost	3838000	USD
CY2011Q3	us-gaap	Contract Revenue Cost ContractRevenueCost	2190000	USD
	us-gaap	Contract Revenue Cost ContractRevenueCost	12740000	USD
	us-gaap	Contract Revenue Cost ContractRevenueCost	3763000	USD
CY2012Q3	us-gaap	Contracts Revenue ContractsRevenue	5583000	USD
CY2011Q3	us-gaap	Contracts Revenue ContractsRevenue	5008000	USD
	us-gaap	Contracts Revenue ContractsRevenue	17328000	USD
	us-gaap	Contracts Revenue ContractsRevenue	8843000	USD
CY2012Q3	us-gaap	Costs And Expenses CostsAndExpenses	12614000	USD
CY2011Q3	us-gaap	Costs And Expenses CostsAndExpenses	8976000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	37680000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	26163000	USD
CY2012Q3	us-gaap	Debt Instrument Basis Spread On Variable Rate DebtInstrumentBasisSpreadOnVariableRate	0.1168
CY2012Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2000000	USD
CY2012Q3	us-gaap	Debt Instrument Increase Additional Borrowings DebtInstrumentIncreaseAdditionalBorrowings	500000	USD
CY2012Q3	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.121
CY2012Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage Rate Range Minimum DebtInstrumentInterestRateStatedPercentageRateRangeMinimum	0.121
CY2012Q3	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	13089	USD
CY2012Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	421000	USD
CY2011Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	386000	USD
CY2012Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	5184000	USD
CY2011Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1980000	USD
CY2012Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	803000	USD
CY2011Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		USD
CY2012Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2500000	USD
CY2011Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2500000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1216000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1197000	USD
CY2011Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	368000	USD
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2012Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	769000	USD
CY2012Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		USD
CY2011Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2012Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3600000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y7M6D
CY2008Q3	us-gaap	Equity Issuance Per Share Amount EquityIssuancePerShareAmount	2.68
CY2012Q3	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.2
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	401000	USD
CY2012Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	769000	USD
CY2011Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	368000	USD
CY2012Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-401000	USD
CY2011Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	736000	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-401000	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	1973000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	26000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2381000	USD
CY2011Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2737000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8291000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8926000	USD
CY2012Q3	us-gaap	Goodwill Goodwill	33141000	USD
CY2011Q4	us-gaap	Goodwill Goodwill	33141000	USD
CY2011Q1	us-gaap	Government Contract Receivable GovernmentContractReceivable	179000000	USD
CY2012Q3	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	1725000	USD
CY2011Q4	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	1836000	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-7217000	USD
CY2011Q3	us-gaap	Investment Income Net InvestmentIncomeNet	22000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	111000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	106000	USD
CY2012Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2011Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2011Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3212000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-20472000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-15247000	USD
CY2012Q3	us-gaap	Investment Income Net InvestmentIncomeNet	39000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3687000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	412000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	504000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-37000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	803000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2500000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	2803000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	271000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-304000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1127000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-111000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	3848000	USD
CY2012Q3	us-gaap	Interest Expense InterestExpense	6000	USD
CY2011Q3	us-gaap	Interest Expense InterestExpense	2000	USD
	us-gaap	Interest Expense InterestExpense	12000	USD
	us-gaap	Interest Expense InterestExpense	6000	USD
CY2012Q3	us-gaap	Liabilities Liabilities	19170000	USD
CY2011Q4	us-gaap	Liabilities Liabilities	12727000	USD
CY2012Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	80546000	USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	66576000	USD
CY2012Q3	us-gaap	Liabilities Current LiabilitiesCurrent	10441000	USD
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7579000	USD
CY2012Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	793000	USD
CY2011Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	300000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <div> <div><!--StartFragment--> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> Note 1 - Organization</p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <br /> </p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Novavax, Inc. (the "Company") is a clinical-stage biopharmaceutical company focused on developing recombinant protein nanoparticle vaccines to address a broad range of infectious diseases. The Company's goal is to become a profitable vaccine company that is aggressively driving towards development, licensure and commercialization of an important portfolio of vaccines worldwide. The Company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles ("VLPs") and recombinant protein micelle vaccines combined with a single-use bioprocessing production system. These vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate immunologically important recombinant proteins. The Company's product pipeline targets a variety of infectious diseases and its vaccine candidates are currently in or have completed clinical trials that target pandemic (H5N1) influenza, seasonal influenza and respiratory syncytial virus ("RSV").</p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <br /> </p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In 2009, the Company formed a joint venture with Cadila Pharmaceuticals Limited ("Cadila") named CPL Biologicals Private Limited (the "JV") to develop and manufacture vaccines, biological therapeutics and diagnostics in India. The JV is owned 20% by the Company and 80% by Cadila. The Company accounts for its investment in the JV using the equity method.</p> <!--EndFragment--></div> </div>
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25920000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9278000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15147000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	17739000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14139000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20760000	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-7217000	USD
CY2011Q3	us-gaap	Net Income Loss NetIncomeLoss	-3212000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20472000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-15659000	USD
CY2012Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2807000	USD
CY2012Q3	us-gaap	Notes Payable Current NotesPayableCurrent	157000	USD
CY2011Q4	us-gaap	Notes Payable Current NotesPayableCurrent	20000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6849000	USD
CY2011Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3968000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20170000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17320000	USD
CY2012Q3	us-gaap	Other Assets Current OtherAssetsCurrent	235000	USD
CY2011Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1558000	USD
CY2012Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	350000	USD
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	469000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	96000	USD
CY2011Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	204000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	141000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-436000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	254000	USD
	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	2800000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	400000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	200000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	15763000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	2082000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	2202000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	414000	USD
CY2012Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2012Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued
CY2012Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding
CY2012Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2011Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0068
CY2011Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2441000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	26925000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9182000	USD
CY2012Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	26900000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	14000000	USD
CY2008Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	17500000	USD
CY2012Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	12100000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	49900000	USD
CY2012Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	800000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	650000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		USD
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-20000	USD
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-60000	USD
	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	-1594000	USD
	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities		USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	2500000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	20235000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	318000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	49000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	156000	USD
CY2012Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9815000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6857000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	90000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations		USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6395000	USD
CY2011Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4049000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16649000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13474000	USD
CY2012Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	838000	USD
CY2011Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue		USD
CY2012Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	756000	USD
CY2011Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent		USD
CY2012Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-350128000	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-329656000	USD
CY2012Q3	us-gaap	Revenues Revenues	5765000	USD
CY2011Q3	us-gaap	Revenues Revenues	5008000	USD
	us-gaap	Revenues Revenues	17510000	USD
	us-gaap	Revenues Revenues	8843000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1668000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1677000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	50000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	53333
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.39
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.63
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	3333
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	5.21
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2011Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2012Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y2M27D
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.7671
CY2011Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.804
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8048
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8048
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.766
CY2011Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7586
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7547
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7328
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0055
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	5559536
CY2012Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1000000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y8M12D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0154
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0191
CY2011Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0048
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0055
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0048
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000	USD
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.09
CY2011Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.78
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.71
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.19
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4600000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
CY2012Q4	us-gaap	Share Price SharePrice	2.18
CY2012Q2	us-gaap	Share Price SharePrice	1.22
CY2012Q3	us-gaap	Stockholders Equity StockholdersEquity	61376000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	53849000	USD
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8400000
CY2008Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6686650
CY2012Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	10000000
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	24957715
CY2011Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	700000
CY2012Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	12385321
CY2012Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	455430
CY2011Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	455430
CY2012Q3	us-gaap	Treasury Stock Value TreasuryStockValue	2450000	USD
CY2011Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2450000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> <strong><em>Use of Estimates</em></strong></p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these estimates.</p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> </p> <!--EndFragment--></div> </div>
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	134178
CY2011Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	115107
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	127246
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	113053

Files In Submission

Name	View Source	Status
0001144204-12-060842-index-headers.html	Edgar Link	pending
0001144204-12-060842-index.html	Edgar Link	pending
0001144204-12-060842.txt	Edgar Link	pending
0001144204-12-060842-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
nvax-20120930.xml	Edgar Link	completed
nvax-20120930.xsd	Edgar Link	pending
nvax-20120930_cal.xml	Edgar Link	unprocessable
nvax-20120930_def.xml	Edgar Link	unprocessable
nvax-20120930_lab.xml	Edgar Link	unprocessable
nvax-20120930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v326292_10q.htm	Edgar Link	pending
v326292_31-1.htm	Edgar Link	pending
v326292_31-2.htm	Edgar Link	pending
v326292_32-1.htm	Edgar Link	pending
v326292_32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVAX
NOVAVAX INC Stock $nvax

2012 Q4 Form 10-Q Financial Statement

#000114420412060842 Filed on November 09, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX NOVAVAX INC Stock $nvax

2012 Q4 Form 10-Q Financial Statement

#000114420412060842 Filed on November 09, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX
NOVAVAX INC Stock $nvax